Natus Medical Inc
NASDAQ:NTUS
Intrinsic Value
Natus Medical, Inc. provides medical device solutions focuses on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of NTUS.
Natus Medical Inc's market capitalization is 1.1B USD.
NTUS stock price is 32.96 USD.
NTUS.
NTUS. Open DCF Valuation
NTUS. Open Relative Valuation
NTUS.
NTUS's Revenue has grown by 14% over the past 12 months.
NTUS's ROIC (Return on Invested Capital) has increased in the last 3 years from 0% to 5%.
NTUS's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 5%.
NTUS's ROE (Return on Equity) has increased in the last 3 years from -3% to 3%.
NTUS's ROE (Return on Equity) for the past 12 months is very low and is equal to 3%.
NTUS has positive Operating Income for the last twelve months.
NTUS has positive Free Cash Flow for the last twelve months.
NTUS has a very low three-year average ROIC (Return on Invested Capital): 2%. The company is not efficient at using invested capital to generate operating income.
NTUS has positive Net Income for the last twelve months.
NTUS has negative three-year average ROE (Return on Equity): -3%. The company is not efficient at transforming stockholders' equity into net income.
NTUS's short-term assets (287m USD) exceed its short-term liabilties (113m USD).
NTUS has positive Gross Profit for the last twelve months.
NTUS's long-term assets (568m USD) exceed its long-term liabilties (137m USD).
NTUS's D/E (Debt to Equity) is very low and is equal to 0.
NTUS's Altman Z-Score is very high and is equal to 5.41.
NTUS earns more than enough operating income (34m USD) to safely cover interest payments on its debt (780k USD).
Fundamental Analysis
Natus Medical Inc
Balance Sheet Decomposition
Natus Medical Inc
| Current Assets | 286.8m |
| Cash & Short-Term Investments | 84.3m |
| Receivables | 103.7m |
| Other Current Assets | 98.8m |
| Non-Current Assets | 281.3m |
| PP&E | 29.4m |
| Intangibles | 59.8m |
| Other Non-Current Assets | 192.1m |
| Current Liabilities | 112.9m |
| Accounts Payable | 34.3m |
| Accrued Liabilities | 51.7m |
| Other Current Liabilities | 26.9m |
| Non-Current Liabilities | 24.3m |
| Other Non-Current Liabilities | 24.3m |
Earnings Waterfall
Natus Medical Inc
|
Revenue
|
478.3m
USD
|
|
Cost of Revenue
|
-205.8m
USD
|
|
Gross Profit
|
272.5m
USD
|
|
Operating Expenses
|
-238.7m
USD
|
|
Operating Income
|
33.8m
USD
|
|
Other Expenses
|
-21.1m
USD
|
|
Net Income
|
12.7m
USD
|
Free Cash Flow Analysis
Natus Medical Inc
NTUS Profitability Score
Profitability Due Diligence
Natus Medical Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Natus Medical Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
NTUS Solvency Score
Solvency Due Diligence
Natus Medical Inc's solvency score is 89/100. The higher the solvency score, the more solvent the company is.
Score
Natus Medical Inc's solvency score is 89/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NTUS Price Targets Summary
Natus Medical Inc
Ownership
NTUS Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
NTUS Price
Natus Medical Inc
| Average Annual Return | -3.63% |
| Standard Deviation of Annual Returns | 47.06% |
| Max Drawdown | -52% |
| Market Capitalization | 1.1B USD |
| Shares Outstanding | 34 582 900 |
| Percentage of Shares Shorted | 6.11% |
Company Profile
Natus Medical Inc
Country
Industry
Market Cap
Dividend Yield
Description
Natus Medical, Inc. provides medical device solutions focuses on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. The company is headquartered in Middleton, Wisconsin and currently employs 1,400 full-time employees. The company went IPO on 2001-07-20. The company provides product solutions for three end markets: Neuro, Newborn Care, and Hearing & Balance. Its Neuro includes products and services that provide diagnostic, therapeutic, and surgical solutions in neurodiagnostic, neurocritical care and neurosurgery. Newborn Care includes products and services for newborn care, including hearing screening, brain monitoring, eye imaging, jaundice management, live video streaming and various disposable newborn care supplies. Hearing & Balance includes products for hearing assessment and diagnostics, and hearing aid fitting, including computer-based audiological, otoneurologic and vestibular instrumentation for hearing care professionals. Its Neuro products and services include Electroencephalography, Electromyography, Polysomnography, Subdural electrodes, and Cranial access kits.
You don't have any saved screeners yet
